I have not been as enthusiastic about the prospects for AgeX as for the parent company but there surely are some eye-catching tidbits in this announcement:
AGEX-BAT1 and AGEX-VASC1 are cell-based therapies in the preclinical stage of development comprised of young regenerative cells formulated in the company's proprietary HyStem® matrix designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively.
Clear as mud, with or without glasses. :-(
From Wikipedia:
Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is needed for cellular metabolism (to keep tissue alive).
That's clear enough and restoring vascular support [veins] is obvious enough but the methodology is not to me [hardly surprising].
In addition to the product candidates in early development, the company, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. In addition, the company, through its ESI BIO division, markets Cytiva®, comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Talk about hitting the ground running :-)
I haven't any idea how the market will react to this wildly futuristic culmination of Dr. West's monumental discovery but it should be a nice diversion from troubled times.
I assume the fees are nothing to write home about but still....
JMO.
est, Terry
Best, Terry
News 
Market Data 
Discover 
